BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 12434560)

  • 1. Participation of peripheral and spinal phosphodiesterases 4 and 5 in inflammatory pain.
    Torres-López JE; Argüelles CF; Granados-Soto V
    Proc West Pharmacol Soc; 2002; 45():141-3. PubMed ID: 12434560
    [No Abstract]   [Full Text] [Related]  

  • 2. Cyclic nucleotides and phosphodiesterases in platelets.
    Haslam RJ; Dickinson NT; Jang EK
    Thromb Haemost; 1999 Aug; 82(2):412-23. PubMed ID: 10605732
    [No Abstract]   [Full Text] [Related]  

  • 3. The effect of Sildenafil on human platelet secretory function is controlled by a complex interplay between phosphodiesterases 2, 3 and 5.
    Dunkern TR; Hatzelmann A
    Cell Signal; 2005 Mar; 17(3):331-9. PubMed ID: 15567064
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Time-dependent involvement of cAMP and cGMP in consolidation of object memory: studies using selective phosphodiesterase type 2, 4 and 5 inhibitors.
    Rutten K; Prickaerts J; Hendrix M; van der Staay FJ; Sik A; Blokland A
    Eur J Pharmacol; 2007 Mar; 558(1-3):107-12. PubMed ID: 17207788
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cyclic nucleotide phosphodiesterases and human arterial smooth muscle cell proliferation.
    Rybalkin SD; Bornfeldt KE
    Thromb Haemost; 1999 Aug; 82(2):424-34. PubMed ID: 10605733
    [No Abstract]   [Full Text] [Related]  

  • 6. Multiplicity within cyclic nucleotide phosphodiesterases.
    Rybalkin SD; Beavo JA
    Biochem Soc Trans; 1996 Nov; 24(4):1005-9. PubMed ID: 8968501
    [No Abstract]   [Full Text] [Related]  

  • 7. Cyclic nucleotide phosphodiesterase 5 and sildenafil: promises realized.
    Manganiello V
    Mol Pharmacol; 2003 Jun; 63(6):1209-11. PubMed ID: 12761329
    [No Abstract]   [Full Text] [Related]  

  • 8. [Levitra (vardenafil)--a new PDE 5 inhibitor for the treatment of erectile dysfunction].
    Katsarov M
    Akush Ginekol (Sofiia); 2004; 43 Suppl 1():31-2. PubMed ID: 15323315
    [No Abstract]   [Full Text] [Related]  

  • 9. [7 years PDE-5 inhibitor for therapy of erection disorders].
    Krankenpfl J; 2005; 43(7-10):267. PubMed ID: 16518894
    [No Abstract]   [Full Text] [Related]  

  • 10. Therapeutic potential of phosphodiesterase 5 inhibition for cardiovascular disease.
    Reffelmann T; Kloner RA
    Circulation; 2003 Jul; 108(2):239-44. PubMed ID: 12860892
    [No Abstract]   [Full Text] [Related]  

  • 11. Sildenafil increases cerebrovascular reactivity: a transcranial Doppler study.
    Brenner S
    Neurology; 2006 May; 66(9):1455-6; author reply 1455-6. PubMed ID: 16682690
    [No Abstract]   [Full Text] [Related]  

  • 12. Vasoactive pharmacotherapy to cure erectile dysfunction: fact or fiction?
    Burnett AL
    Urology; 2005 Feb; 65(2):224-30. PubMed ID: 15708027
    [No Abstract]   [Full Text] [Related]  

  • 13. [Therapy of erectile dysfunction. Hard facts support sildenafil].
    MMW Fortschr Med; 2003 Sep; 145(35-36):50-1. PubMed ID: 14584211
    [No Abstract]   [Full Text] [Related]  

  • 14. [Comparison of efficacy and safety of phosphodiesterase type 5 inhibitors in the treatment of erectile dysfunction].
    Chen Q; Wang N; Yao F; Lu X
    Zhonghua Nan Ke Xue; 2004 Apr; 10(4):302-4. PubMed ID: 15148932
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Oral drug treatment of erectile dysfunction.
    Int J Impot Res; 2003 Dec; 15 Suppl 7():S27-9. PubMed ID: 14695970
    [No Abstract]   [Full Text] [Related]  

  • 16. [In sex dysfunctions--not just a "male issue". Don't forget women].
    MMW Fortschr Med; 2003 Sep; 145(35-36):51. PubMed ID: 14584212
    [No Abstract]   [Full Text] [Related]  

  • 17. The role of phosphodiesterase isoforms 2, 5, and 9 in the regulation of NO-dependent and NO-independent cGMP production in the rat cervical spinal cord.
    de Vente J; Markerink-van Ittersum M; Vles JS
    J Chem Neuroanat; 2006 Jun; 31(4):275-303. PubMed ID: 16621445
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cyclic nucleotide phosphodiesterases: gene complexity, regulation by phosphorylation, and physiological implications.
    Burns F; Zhao AZ; Beavo JA
    Adv Pharmacol; 1996; 36():29-48. PubMed ID: 8783553
    [No Abstract]   [Full Text] [Related]  

  • 19. Cyclic nucleotide phosphodiesterases and their role in immunomodulatory responses: advances in the development of specific phosphodiesterase inhibitors.
    Castro A; Jerez MJ; Gil C; Martinez A
    Med Res Rev; 2005 Mar; 25(2):229-44. PubMed ID: 15514991
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Asthma and airway inflammation: potential anti-inflammatory activities of phosphodiesterase inhibitors.
    Lagente V; Hichami A; Boichot E; Martins MA; Silva PM
    Allerg Immunol (Paris); 1995 Feb; 27(2):34-9. PubMed ID: 7710653
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.